AKT1 and melanoma: In vivo studies demonstrated that low-dose artemisinin inhibited UM melanoma tumor growth by up to 50%, whereas a 75% reduction was observed in high-dose animals by a mechanism related to PI3K/AKT/mTOR signaling, suggesting that its antitumor effects may occur by targeting this pathway [166].